INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness

Core Insights - INmune Bio Inc. has partnered with the Cell and Gene Therapy Catapult to establish large-scale manufacturing for its cell therapy platforms, enhancing its production capabilities for commercial readiness [1][3] Company Overview - INmune Bio is a clinical-stage biotechnology company focused on harnessing the innate immune system to treat diseases such as Alzheimer's, prostate cancer, and recessive dystrophic epidermolysis bullosa (RDEB) [2][8] - The company has a diversified portfolio with active trials in the UK, Europe, Australia, Canada, and the US, addressing significant unmet medical needs [2] Collaboration Details - The partnership with CGT Catapult will leverage its expertise at the Stevenage Manufacturing Innovation Centre, initially focusing on scaling production of CORDStrom™, a therapy for RDEB [3][4] - CORDStrom™ has shown promise in a Phase 2 trial, reducing pain and itch while potentially improving skin integrity and disease activity, with an estimated 4,000 children in the US, UK, and EU who could benefit [3] Future Plans - Following CORDStrom™, INmune Bio plans to transition production of INKmune®, its NK-priming cell medicine for solid tumors, to the same facility, supporting ongoing trials in the US and UK [4] - This collaboration is expected to accelerate the company's path to commercialization by providing efficient, scalable manufacturing while maintaining operational control [4] Industry Context - The Cell and Gene Therapy Catapult aims to advance the cell and gene therapy industry, creating collaborations to overcome challenges and support the development of life-changing therapies [6]